

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Approximately what percentage of patients receiving talquetamab for relapsed/refractory (R/R) multiple myeloma (MM) in the MonumentAL-1 trial developed immune effector cell-associated neurotoxicity syndrome?
  - a. Less than 1%
  - b. 10%**
  - c. 25%
  - d. Greater than 30%
2. In addition to CD3, the bispecific antibody cevostamab also targets which of the following proteins?
  - a. GPRC5D
  - b. CD30
  - c. FcRH5**
  - d. NKG2
3. Which of the following Grade 3 to 4 nonhematologic adverse events was most commonly observed in patients receiving mezigdomide for R/R MM in a Phase I/II trial?
  - a. Dry mouth
  - b. Infections**
  - c. Keratopathy
  - d. Rash
4. What was the approximate overall response rate with elranatamab monotherapy for patients with R/R MM and no prior exposure to B-cell maturation antigen (BCMA)-targeted therapy in the Phase II MagnetisMM-3 trial?
  - a. 11%
  - a. 21%
  - b. 41%
  - d. 61%**
5. Which of the following statements best describes the correlation between baseline tumor BCMA expression and response to teclistamab in the Phase I/II MajesTEC-1 study?
  - a. Response was directly proportional to BCMA expression
  - b. Response was inversely proportional to BCMA expression
  - c. Response was independent of BCMA expression**